We are live on ! Find out more
FATE icon

Fate Therapeutics
FATE

53 hedge funds and large institutions have $114M invested in Fate Therapeutics in 2017 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 4

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

97% more capital invested

Capital invested by funds: $57.9M → $114M (+$56M)

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

43% more funds holding

Funds holding: 37 → 53 (+16)

7.26% less ownership

Funds ownership: 67.73% → 60.47% (-7.3%)

Holders
53
Holders Change
+16
Holders Change %
+43.24%
% of All Funds
1.32%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
24
Increased
11
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$9.28M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.92M
3
6CM
683 Capital Management
New York
+$1.72M
4
Wells Fargo
Wells Fargo
California
+$928K
5
Millennium Management
Millennium Management
New York
+$717K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$6.64M
2
KCM
Kingdon Capital Management
New York
-$3.31M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$122K
4
PA
Parallel Advisors
California
-$63K
5
AIM
Acrospire Investment Management
Illinois
-$48.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$157K -$19.5K -5,318 -13%
DCM
27
Driehaus Capital Management
Illinois
$145K +$116K +31,790 New
PAM
28
Panagora Asset Management
Massachusetts
$134K – – –
Squarepoint
29
Squarepoint
New York
$131K +$32.6K +8,900 +45%
Barclays
30
Barclays
United Kingdom
$115K +$92K +25,143 New
VKH
31
Virtu KCG Holdings
New York
$111K +$6.45K +1,764 +8%
Creative Planning
32
Creative Planning
Kansas
$105K +$21.9K +6,000 +35%
DTL
33
Dynamic Technology Lab
Singapore
$99K +$79.2K +21,654 New
GP
34
GLG Partners
United Kingdom
$94K +$75.9K +20,754 New
BCM
35
BlueCrest Capital Management
Jersey
$81K +$64.9K +17,728 New
TAM
36
Tocqueville Asset Management
New York
$68K – – –
Citadel Advisors
37
Citadel Advisors
Florida
$63K +$50.3K +13,746 New
Cerity Partners
38
Cerity Partners
New York
$63K +$50.9K +13,920 New
Invesco
39
Invesco
Georgia
$57K +$45.6K +12,465 New
CS
40
Credit Suisse
Switzerland
$56K +$45.3K +12,372 New
AIM
41
Acrospire Investment Management
Illinois
$40K -$48.6K -13,288 -60%
CB
42
Community Bank
New York
$30K +$23.8K +6,500 New
IA
43
IFP Advisors
Florida
$25K -$24.3K -6,640 -55%
JP Morgan Chase
44
JP Morgan Chase
New York
$10K +$7.92K +2,166 New
AG
45
Advisor Group
Arizona
$9K – – –
First Manhattan
46
First Manhattan
New York
$5K -$1.83K -500 -29%
VCM
47
Vigilant Capital Management
Maine
$5K +$3.66K +1,000 New
Federated Hermes
48
Federated Hermes
Pennsylvania
$5K +$4.28K +1,170 New
DADC
49
D.A. Davidson & Co
Montana
$3K – – –
TWA
50
TCI Wealth Advisors
Arizona
$2K – – –
1
2
3

FATE Hedge Fund Activity: Q1 2017 in Review

53 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2017, worth a combined $114M — up 97% from $57.9M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new FATE positions and 4 closed out — a net gain of 20 holders — while 11 added to existing stakes and 7 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $9.28M. The largest seller was BVF Inc, cutting an estimated $6.64M.

  • 53 institutional investors held Fate Therapeutics (FATE) as of Q1 2017, up from 37 in Q4 2016.
  • Funds reported $114M of Fate Therapeutics stock for Q1 2017, up 97% quarter-over-quarter.
  • 24 funds opened new Fate Therapeutics positions in Q1 2017 and 4 closed out, a net change of +20 holders.
  • The largest Fate Therapeutics buyer in Q1 2017 was EcoR1 Capital, an estimated $9.28M added.
  • The largest Fate Therapeutics seller in Q1 2017 was BVF Inc, an estimated $6.64M sold.

Based on aggregated 13F filings for Q1 2017.